Talal Hilal, MD
Hematology & Oncology · Phoenix, AZNPI 1669813978
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,098 of the $5,618 with a category attached, or 72.9%. 29 manufacturers reported payments, led by Beone Medicines USA, Inc. at 43.5% of the total. 2025 is the largest year on record at $2,799, more than ten times the $29 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in AZ, where the typical reported total is $6,870.
Across 56 payments — averaging $100.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beone Medicines USA, Inc.$2K
- Incyte Corporation$2K
- AbbVie$183
- Sobi, Inc$168
- Bristol Myers Squibb$137
- E.r. Squibb & Sons, L.L.C.$133
- plus $770 from 23 others
Across 15 payments — averaging $22,089 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$211K
- Beone Medicines USA, Inc.$53K
- Beone Medicines Ltd.$34K
- Beigene USA, Inc.$24K
- E.r. Squibb & Sons, L.L.C.$10K
What the payments were for
- Consulting fees$4,09873%
- Food & beverage$1,39225%
- Education$1282%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beone Medicines USA, Inc. | 2 | $2,445 |
| Incyte Corporation | 6 | $1,783 |
| AbbVie | 5 | $183 |
| Sobi, Inc | 1 | $168 |
| Bristol Myers Squibb | 3 | $137 |
| E.r. Squibb & Sons, L.L.C. | 2 | $133 |
| Seagen Inc. | 4 | $110 |
| AstraZeneca | 3 | $110 |
| Pharming Healthcare, Inc. | 1 | $98 |
| Karyopharm Therapeutics Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $39 |
| Servier Pharmaceuticals LLC | 2 | $37 |
| Genentech USA, Inc. | 2 | $32 |
| Novartis | 2 | $31 |
| Rigel Pharmaceuticals, Inc. | 2 | $29 |
| Pfizer | 2 | $29 |
| Johnson & Johnson | 2 | $27 |
| Morphosys, US Inc. | 1 | $19 |
| Beigene USA, Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Emmaus Medical, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Exelixis Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Adaptive Biotechnologies Corporation | 1 | $14 |
| Foundation Medicine, Inc. | 1 | $13 |
| Amgen | 1 | $13 |
| Secura Bio, Inc. | 1 | $12 |
| Tersera Therapeutics LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,618 in reported general payments places this provider in the 45th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 34 | $402,048 |
| VenclextaVenetoclax | 46 | $355,864 |
| RevlimidLenalidomide | 24 | $311,664 |
| CalquenceAcalabrutinib Maleate | 13 | $163,665 |
| EliquisApixaban | 14 | $8,005 |
| Fentanyl | 11 | $1,341 |
| Acyclovir | 72 | $1,103 |
| Oxycodone Hcl | 14 | $466 |
| Lorazepam | 13 | $193 |
| Prochlorperazine Maleate | 21 | $155 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $87 |
| Ondansetron Hcl | 14 | $62 |
| Allopurinol | 17 | $61 |
| Prednisone | 19 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $17 | $402,04834 claims |
| AbbVieVenclexta | $183 | $355,86446 claims |
| Bristol Myers SquibbRevlimid | $137 | $311,66424 claims |
| AstraZenecaCalquence | $110 | $163,66513 claims |
| PfizerEliquis | $29 | $8,00514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Phoenix
- Javier MunozPhoenix$638K
- Mazen KhattabPhoenix$186K
- Robert GalamagaPhoenix$168K
- Panayiotis SavvidesPhoenix$153K
- Robert YooPhoenix$44K
- Sunil TulpulePhoenix$36K
- Tania CortasPhoenix$33K
- Mahesh SeetharamPhoenix$30K
- Boo Ghee LowPhoenix$25K
- Sujith KalmadiChandler$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.